Widely used:Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹417 Cr
Revenue (TTM)
₹133 Cr
Net Profit (TTM)
₹4 Cr
ROE
-6 %
ROCE
3.3 %
P/E Ratio
101.3
P/B Ratio
4.1
Industry P/E
101.25
EV/EBITDA
25.5
Div. Yield
0 %
Debt to Equity
1
Book Value
₹28.5
EPS
₹1.1
Face value
10
Shares outstanding
35,690,000
CFO
₹300.62 Cr
EBITDA
₹224.39 Cr
Net Profit
₹-87.93 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Lyka Labs
| -25.9 | 0.5 | -1.2 | 4.2 | -5.9 | 49.5 | 6.2 |
|
BSE Healthcare
| -5.9 | 0.5 | 7.3 | 18.6 | 22.8 | 22.3 | 9.5 |
|
BSE Small Cap
| -6.0 | 4.8 | 12.4 | 7.4 | 25.0 | 37.4 | 16.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Lyka Labs
| 27.9 | -4.6 | -41.7 | 582.9 | 57.4 | -35.1 | -53.2 |
|
BSE Small Cap
| 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 | -23.4 |
|
BSE Healthcare
| 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 | -5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Lyka Labs
|
116.9 | 416.9 | 132.8 | 3.8 | 5.7 | 4.9 | 101.3 | 4.1 |
| 252.1 | 3,954.9 | 2,711.5 | 3.2 | 6.5 | 0.5 | -- | 0.7 | |
| 52.1 | 15.9 | 0.6 | 0.4 | 65.5 | 10.5 | 41.1 | 4.0 | |
| 246.7 | 11,181.8 | 2,622.8 | 382.6 | 17.0 | 16 | 29.4 | 4.5 | |
| 30.7 | 923.7 | 1,006.4 | 46.5 | 8.0 | 11 | 19.9 | 2.1 | |
| 5,009.8 | 11,544.1 | 667.6 | 168.3 | 37.0 | 82.8 | 68.6 | 35.8 | |
| 9.6 | 144.7 | 13.2 | -68.3 | -175.4 | -- | -- | -17.5 | |
| 38.0 | 68.1 | 46.7 | 7.3 | 24.6 | 10.6 | 9.4 | 0.9 |
No Review & Analysis are available.
Lyka Labs Limited, a pharmaceutical company, develops, manufactures, and markets pharmaceutical formulations and active pharmaceutical ingredients across various therapeutic segments in India. The company manufactures and sells various formulations,... including emollient, topical steroid, antifungal agent, topical anti-bacterial, acne management, dermatological formulation, pain killer, anti-aging, cleansing lotion, hair care, anti-dandruff shampoo, sunscreen, anti-acne, cosmeceutical, anti-oxidant, proton pump inhibitor, nutraceuticals, anti-malarial, anti-bacterial, corticosteroid hormones, cephalosporin, dry powder injection, bone resorption inhibitor, anti-oxidant/liver disease, antibiotic, and lyophilized products. It also offers contracted manufacturing services to various large pharmaceutical companies; and medical and technical assistance in the areas of manufacturing know how and manufacturing facilities, as well as technical data, such as molecule stability testing data, impurity profile, and BA/BE clinical study data. In addition, it provides products and services in therapeutic categories, such as intensive care, gastroenterology, anti-infective, anti-fungal, surgery care, cosmetologist, urology, wound care, and anesthesia. The company offers its products in various forms, including injections, creams, ointments, foams, gels, and lotions. It also exports its products. The company was incorporated in 1976 and is based in Mumbai, India. Read more
Incorporated
1976
Chairman
Babulal Jain
Managing Director
Kunal N Gandhi
Headquarters
Ankleshwar, Gujarat
Website
Looking for more details about Lyka Labs Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The total asset value of Lyka Labs Ltd stood at ₹ 168 Cr as on 31-Dec-24
The share price of Lyka Labs Ltd is ₹116.93 (NSE) and ₹116.80 (BSE) as of 23-May-2025 IST. Lyka Labs Ltd has given a return of -5.93% in the last 3 years.
Lyka Labs Ltd has a market capitalisation of ₹ 417 Cr as on 23-May-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Lyka Labs Ltd is 4.10 times as on 23-May-2025, a 341% premium to its peers’ median range of 0.93 times.
The P/E ratio of Lyka Labs Ltd is 101.25 times as on 23-May-2025, a 0% premium to its peers’ median range of 101.25 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Lyka Labs Ltd and enter the required number of quantities and click on buy to purchase the shares of Lyka Labs Ltd.
Lyka Labs Limited, a pharmaceutical company, develops, manufactures, and markets pharmaceutical formulations and active pharmaceutical ingredients across various therapeutic segments in India. The company manufactures and sells various formulations, including emollient, topical steroid, antifungal agent, topical anti-bacterial, acne management, dermatological formulation, pain killer, anti-aging, cleansing lotion, hair care, anti-dandruff shampoo, sunscreen, anti-acne, cosmeceutical, anti-oxidant, proton pump inhibitor, nutraceuticals, anti-malarial, anti-bacterial, corticosteroid hormones, cephalosporin, dry powder injection, bone resorption inhibitor, anti-oxidant/liver disease, antibiotic, and lyophilized products. It also offers contracted manufacturing services to various large pharmaceutical companies; and medical and technical assistance in the areas of manufacturing know how and manufacturing facilities, as well as technical data, such as molecule stability testing data, impurity profile, and BA/BE clinical study data. In addition, it provides products and services in therapeutic categories, such as intensive care, gastroenterology, anti-infective, anti-fungal, surgery care, cosmetologist, urology, wound care, and anesthesia. The company offers its products in various forms, including injections, creams, ointments, foams, gels, and lotions. It also exports its products. The company was incorporated in 1976 and is based in Mumbai, India.
The prominent promoters of Lyka Labs Ltd. are
| Name of promoters | Holding percentage |
|---|---|
|
IPCA LABORATORIES LIMITED |
40.98%
|
|
KUNAL NARENDRA GANDHI |
9.79%
|
|
NEHAL NARENDRA GANDHI |
3.46%
|
|
ENAI TRADING AND INVESTMENT PVT. LTD |
2.8%
|
The chairman of the company is Babulal Jain, and the managing director is Kunal N Gandhi.
There is no promoter pledging in Lyka Labs Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
3,955
|
|
|
145
|
|
|
68
|
|
|
16
|
|
|
11,544
|
|
|
11,182
|
|
|
3,955
|
|
|
924
|
|
|
145
|
| Lyka Labs Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
4.89
|
|
Operating margin(%)
|
5.74
|
|
Net Margin(%)
|
2.84
|
|
Dividend yield(%)
|
0
|
Yes, TTM profit after tax of Lyka Labs Ltd was ₹4 Cr.
₹-1.18
(
